Uridine and Butyrate Fiber Composition for Stool Transit Time
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compositions and treatments for constipation, particularly slow transit constipation, do not effectively address the issue of improving stool transit time and colon length disorders, nor do they utilize uridine derivatives and butyrate-producing fibers to enhance gastrointestinal health.
Innovation Solution
A composition comprising uridine derivatives, specifically uridine monophosphate (UMP), combined with butyrate-producing fibers, is administered to improve intestinal transit time and reduce alpha-synuclein aggregates in the gastrointestinal tract, thereby alleviating constipation and enhancing stool consistency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If conventional treatments and compositions are used for constipation, then general gastrointestinal symptoms may be addressed, but stool transit time improvement and colon length disorder treatment are ineffective
Solution Approach 1:
The patent combines uridine derivatives (such as UMP) with butyrate-producing fibers (such as inulin, FOS, GOS, or resistant starch) into a single composition. This merging of two distinct functional components creates a synergistic effect where uridine supports intestinal epithelial cell proliferation and butyrate-producing fibers stimulate butyrate generation, together effectively improving stool transit time and treating colon length disorders better than either component alone.
Solution Approach 2:
The invention creates a composite functional composition integrating uridine derivatives and butyrate-producing fibers. This composite approach leverages the complementary mechanisms of both components: uridine's role in cell membrane synthesis and epithelial regeneration, and butyrate's role as an energy source for colonocytes and anti-inflammatory agent, resulting in a reliable treatment for slow transit constipation and colon length disorders.
2Object-generated harmful factors
If dietary fibers alone are used, then stool bulk may increase, but alpha-synuclein aggregates are not effectively reduced and transit time improvement is limited
Solution Approach 1:
The patent merges uridine derivatives with butyrate-producing fibers to create a composition that addresses multiple pathological mechanisms simultaneously. Uridine has been shown to reduce alpha-synuclein aggregation through its metabolic effects, while butyrate-producing fibers reduce inflammation and provide energy for intestinal cells. This combination effectively reduces alpha-synuclein aggregates without requiring complex multi-component formulations.
3Quantity of substance
If uridine derivatives are used alone, then intestinal cell proliferation may be supported, but butyrate production and associated gastrointestinal benefits are insufficient
Solution Approach 1:
The patent utilizes butyrate-producing fibers that serve as substrates for endogenous butyrate production by colonic microbiota. Instead of requiring external butyrate supplementation or complex synthesis processes, the composition enables the body's own microbial communities to convert the fiber components into butyrate, simplifying manufacturing while ensuring adequate butyrate production through natural physiological processes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination significantly improves stool transit time and colon length, effectively treating slow transit constipation and reducing alpha-synuclein aggregates, as demonstrated in mouse models, with potential applications in humans, especially the elderly and those with Parkinson's disease.
Implementation Method 1
butyrate producing fibres
Implementation Method 2
uridine source, specifically uridine monophosphate (UMP), combined with butyrate-producing fibers, is administered to improve intestinal transit time and reduce alpha-synuclein aggregates
Data Source
Figure 1
Figure 2~3
AI summary
The present invention provides for a composition comprising a uridine source and butyrate producing fibers for use in the prevention or treatment of constipation, transit time dysfunction or colon length disorder. Said composition may also be used for the improvement of stool consistency. Advantageously said composition further comprises omega-3 polyunsaturated fatty acids such as DHA and/or EPA and a vitamin supplement comprising at least vitamin D3.